EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

LRH-1 is a novel regulator of neutrophil-driven immune responses within the tumor microenvironment

Yu Wang, Bryan Duong, Sam Keeley, Natalia Krawczynska, Shruti V Bendre, Claire P Schane, Dhanya Pradeep, Desirée Rodríguez-Casiano, Erin Weisser, Nadia Cobo-Vuilleumier, Sabrina Akter, Lara Kockaya und 12 weitere

Cancer Letters · 2026-12 · 662 · 218910

DOI: 10.1016/j.canlet.2026.218910 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026-12. Verfasst von Yu Wang und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Integrative Physiology, University of Illinois Urbana Champaign, Illinois, USA. Hauptthemen laut MEDLINE: Neutrophils, Receptors, Cytoplasmic and Nuclear, Tumor Microenvironment. Die Arbeit nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIGMS NIH HHS, NCI NIH HHS, NIEHS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Plasma cholesterol is correlated with worse outcomes in breast and ovarian cancer. Prior work indicates that myeloid immune cells are highly responsive to cholesterol metabolism. Interestingly, Liver Receptor Homolog-1 (LRH-1, or NR5A2), a key transcriptional regulator of cholesterol homeostasis is highly expressed in neutrophils and is associated with increased survival time. However, the roles of LRH-1 within neutrophils remain unclear. We therefore focused on how LRH-1 influences neutrophil behaviors relevant to cancer. Small molecule ligands for LRH-1 regulated neutrophil migration towards cancer cells. Phagocytosis was also regulated by LRH-1 ligands, the extent being dependent on type of bait (e. coli vs. cancer cells). In T cell co-cultures, neutrophils pretreated with an LRH-1 agonist promoted greater T cell expansion, particularly in CD4+ cells, while LRH-1 inhibition suppressed this response. NETosis is a known trigger of recurrence from dormancy and subsequent tumor growth. Importantly LRH-1 activation reduced NETosis, while treatment with an antagonist or inverse agonist enhanced NETosis, likely through altered reactive oxygen species. Treatment of mice with an inverse agonist of LRH-1 increased the growth of mammary tumors in a NET-dependent manner. Mice harboring dormant D2.0R mammary cancer lesions treated with an LRH-1 inverse agonist exhibited earlier tumor recurrence and enhanced metastatic progression. In contrast, treatment with BL001, a small chemical LRH-1 agonist, delayed recurrence in D2.0R-grafted mice. These findings reveal that LRH-1 is a novel regulator of neutrophil-driven immune responses within the tumor microenvironment. LRH-1 is thus a promising therapeutic target to suppress the progression of breast and ovarian cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeutrophilsReceptors, Cytoplasmic and NuclearTumor MicroenvironmentAnimalsHumansFemaleMiceCell Line, TumorPhagocytosisCoculture TechniquesExtracellular TrapsMice, Inbred C57BL

Stichwörter der Autor:innen

Breast cancerCholesterolDormancyLRH-1Liver receptor homolog 1Myeloid cellNR5A2NeutrophilNuclear receptorOvarian cancer

Substanzen

Receptors, Cytoplasmic and NuclearNR5A2 protein, humanNr5a2 protein, mouse

Autor:innen und Institutionen

  • Department of Molecular and Integrative Physiology, University of Illinois Urbana Champaign, Illinois, USA.
  • Department of Molecular and Integrative Physiology, University of Illinois Urbana Champaign, Illinois, USA; Beckman Institute for Advanced Science and Technology, University of Illinois Urbana Champaign, Illinois, USA.
  • Andalusian Center of Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucía-University of Pablo de Olavide-University of Seville-CSIC, Seville, Spain.
  • Department of Food Science and Human Nutrition, University of Illinois Urbana Champaign, Illinois, USA.
  • Roy J. Carver Biotechnology Center, University of Illinois Urbana Champaign, Urbana, IL, 61801, USA.
  • National Center for Supercomputing Applications, University of Illinois Urbana Champaign, Illinois, USA.

Förderung

  • NIGMS NIH HHS
  • NCI NIH HHS
  • NIEHS NIH HHS
  • NIBIB NIH HHS
  • University of Illinois Urbana-Champaign Beckman Institute for Advanced Science and Technology
  • National Institutes of Health

Zitieren

APA

Wang, Y., Duong, B., Keeley, S., Krawczynska, N., Bendre, S. V., Schane, C. P., Pradeep, D., Rodríguez-Casiano, D., Weisser, E., Cobo-Vuilleumier, N., Akter, S., Kockaya, L., Fei, Y., Gupta, A. D., Vidana Gamage, H. E., Nelczyk, A. T., He, S., Kim, H., Yoo, J. Y., …, & Nelson, E. R. (2026). LRH-1 is a novel regulator of neutrophil-driven immune responses within the tumor microenvironment. Cancer Letters, 662, 218910. https://doi.org/10.1016/j.canlet.2026.218910

Vancouver

Wang Y, Duong B, Keeley S, Krawczynska N, Bendre SV, Schane CP, et al. LRH-1 is a novel regulator of neutrophil-driven immune responses within the tumor microenvironment. Cancer Letters. 2026;662:218910. doi:10.1016/j.canlet.2026.218910

BibTeX
@article{Wang2026,
  author = {Wang, Yu and Duong, Bryan and Keeley, Sam and Krawczynska, Natalia and Bendre, Shruti V and Schane, Claire P and Pradeep, Dhanya and Rodríguez-Casiano, Desirée and Weisser, Erin and Cobo-Vuilleumier, Nadia and Akter, Sabrina and Kockaya, Lara and Fei, Yifan and Gupta, Anasuya Das and Vidana Gamage, Hashni Epa and Nelczyk, Adam T and He, Sisi and Kim, Hannah and Yoo, Jin Young and Drnevich, Jenny and Soliman, Aiman and Madak-Erdogan, Zeynep and Gauthier, Benoit R and Nelson, Erik R},
  title = {LRH-1 is a novel regulator of neutrophil-driven immune responses within the tumor microenvironment},
  journal = {Cancer Letters},
  year = {2026},
  volume = {662},
  pages = {218910},
  doi = {10.1016/j.canlet.2026.218910}
}
Kostenlos starten →